butadiene* OR (carbon ADJ monoxide*) OR co OR carbonmonoxide* OR Coarse OR dust OR ethane OR ethylbenzene* OR ethylene* OR ethene* OR particle* OR (particul* ADJ3 matter*) OR (nitro* ADJ dioxide*) OR pm1 OR "pm2 5" OR pm10 OR "pm 1" OR "pm 2 5" OR "pm 10" OR soot OR toluene* OR xylene* OR ufp* OR "black carbon" OR (polycyclic ADJ3 (hydrocarbon* OR carbon*)) OR pah OR pahs OR combust* OR (volatile ADJ3 compound*) OR VOCs OR voc OR tVOCs OR tvoc OR btex OR smoke OR smoking OR tobacco OR (carbon ADJ3 nanotube*)).ab,ti.) AND (exp "Lymphocytes"/ OR exp "Cytokines"/ OR (((lymphoid ) ADJ3 cell*) OR lymphocyte* OR ilc OR ilcs OR (natural* ADJ3 killer*) OR cytokine* OR interferon* OR ifn OR interleukin*).ab,ti.) AND (asthma/ OR "respiratory tract infection"/ OR "respiratory tract inflammation"/ OR (asthma* OR (airway* ADJ6 (hyperreactiv* OR allerg* OR inflammat* OR immun*)) OR ((respiratory* OR airway*) ADJ3 infect*)).ab,ti.) AND ("Immunity, Innate"/ OR (innate* OR non-specific* OR nonspecific* OR in-born OR inborn ).ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. Dysregulation of ILC2s and TH2 cells attenuates DEPenhanced allergic airway inflammation. In addition, a crucial role for the adaptive immune system was shown on concomitant DEP+HDM exposure.
• Type 2 cytokine production Lung-resident ILC2s were the predominant early source of the Th2 cytokines IL-5 and IL-13 in O3-exposed mice.
• ILC2s and RNA extraction from removed lungs
• Activates lung-resident ILC2
• Increased IL-5 by lung ILC2s in response to IL-33.
• Induced IL-33 mRNA activation and increased protein expression in the lung tissue in both strains.
• No ILC2 influx or proliferation within 12 hours after O3 exposure.
• ILC2s from the lungs: greater increased activation of Il5 and Il13 mRNA 12 hours after O3
• BAL IL-4 and IL-5 expression
• ILC2s O3 did not induce IL-5 or IL-13 production by CD41Thy11 TH cells isolated from the lungs 12 hours after exposure • LC2s mediate O3-induced airway inflammation and AHR Kumagai K, et al. 2017 Mice Groups in vivo ex vivo O3 Dose: 0.8 ppm Route: Inhaled 1 day or 9 consecutive weekday (4 hr/day).
(depleted of all lymphoid cells including ILCs) 6. Air Rag2 -/-Il2rg -/-
• Mucous Cell Metaplasia O3 C57BL/6 vs other groups:
• Mucous cell metaplasia • Greater volume densities of mucosubstances in airway epithelium lining this proximal largediameter Murine ILCs, but not T or B cells, play a crucial rule in ozone-induced mucous cell metaplasia, eosinophilic inflammation, and type 2 immunity in the lungs of mice.
• Gene expression in type2 immune response
• Increased expression of genes involved in type 2 immune responses
• Number ILCs • A small number of ILCs were present in ozoneexposed Rag2 / Air-and ozone exposed Rag2 / mice had statistically similar numbers of lung ILC2s Cytokine production DEP vs. Saline • DEP stimulate production of IL-6 • IFN-γ levels were considerably decreased, in some experiments decrease was 75% when mice were injected with DEP on 3 successive days DEP potently inhibits IFN-γ production by NK and NKT cells, which is rapid in onset, long lasting, and dose related. DEP induces an inhibitory effect on steady state INF-γ mRNA levels, and may also suppress INF-γ production through posttranscriptional mechanisms.
TLRL4-induced IFN-γ production,
• Injection of 2 mg of DEP 2 h before LPS administration completely suppressed the LPSinduced IFN-γ response and partially suppressed LPS-induced IL-10 production, but had no effect on LPS induction of IL-6 or TNF production • DEP suppressed the LPS-induced increase in IFN-γ mRNA (although not as completely as it suppressed IFN-γ secretion.
NK and NKT
• DEP suppressed IFN-γ production individual NK and NKT cells following LPS stimulation • DEP failed to suppress anti-CD3 mAb-induced production of IFN-γ, or other cytokines, which are NKT cell derived. Zhao H, et Provide an accurate summary of the background, research objectives, including details of the species or strain of animal used, key methods, principal findings and conclusions of the study.
INTRODUCTION
Background 3 a. Include sufficient scientific background (including relevant references to previous work) to understand the motivation and context for the study, and explain the experimental approach and rationale.
100
b. Explain how and why the animal species and model being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.
50
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being tested. 100 Provide an accurate summary of the background, research objectives, including details of the species or strain of animal used, key methods, principal findings and conclusions of the study.
METHODS

Ethical statement
INTRODUCTION
100
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being tested. 100
METHODS
Ethical statement 5
Indicate the nature of the ethical review permissions, written informed consent 100
Study design 6 For each experiment, give brief details of the study design including the number of experimental and control groups. 75
In vitro procedures 7 a. Describe in detail all the in vitro procedures 100 b. Describe in detail all the reagents, cells, kits including manufacturer used (manufacturer) 100
Sample size 10 a. Specify the total number of subjects 100
b. Explain how the number of animals was arrived at. Provide details of any sample size calculation used. 0
Experimental outcomes 12
Clearly define the primary and secondary experimental outcomes assessed (e.g. cell death, molecular markers, behavioural changes). 100
Statistical methods 13 a. Provide details of the statistical methods used for each analysis. 75 b. Describe any methods used to assess whether the data met the assumptions of the statistical approach. 100 
RESULTS
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